source
- BlossomHill Therapeutics targets $112 million IPO to fund EGFR lung-cancer drug BH-30643BlossomHill Therapeutics, a San Diego oncology biotech, announced plans for an initial public offering to raise about $112 million. The company intends to sell 7.8 million shares at $15-$17 each,…
- FDA releases new guidances on adhesive performance and skin irritation studies for transdermal generic drugsThe U.S. Food and Drug Administration has issued two new guidances that address transdermal or topical delivery systems for generic drugs. One is a final guidance that outlines how to assess adhesi…